- Home
- ISDR vs BCTX Comparison
ISDR vs BCTX Comparison
Compare ISDR & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISDR
- BCTX
- Stock Information
- Founded
- ISDR 1988
- BCTX 2014
- Country
- ISDR United States
- BCTX Canada
- Employees
- ISDR N/A
- BCTX N/A
- Industry
- ISDR Publishing
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- ISDR Consumer Discretionary
- BCTX Health Care
- Exchange
- ISDR Nasdaq
- BCTX Nasdaq
- Market Cap
- ISDR 37.2M
- BCTX 34.6M
- IPO Year
- ISDR N/A
- BCTX N/A
- Fundamental
- Price
- ISDR $9.10
- BCTX $0.56
- Analyst Decision
- ISDR
- BCTX Strong Buy
- Analyst Count
- ISDR 0
- BCTX 1
- Target Price
- ISDR N/A
- BCTX $15.00
- AVG Volume (30 Days)
- ISDR 6.3K
- BCTX 2.4M
- Earning Date
- ISDR 11-07-2024
- BCTX 12-16-2024
- Dividend Yield
- ISDR N/A
- BCTX N/A
- EPS Growth
- ISDR N/A
- BCTX N/A
- EPS
- ISDR N/A
- BCTX N/A
- Revenue
- ISDR $29,141,000.00
- BCTX N/A
- Revenue This Year
- ISDR N/A
- BCTX N/A
- Revenue Next Year
- ISDR N/A
- BCTX N/A
- P/E Ratio
- ISDR N/A
- BCTX N/A
- Revenue Growth
- ISDR N/A
- BCTX N/A
- 52 Week Low
- ISDR $7.61
- BCTX $0.46
- 52 Week High
- ISDR $19.03
- BCTX $5.97
- Technical
- Relative Strength Index (RSI)
- ISDR 41.20
- BCTX 38.43
- Support Level
- ISDR $8.62
- BCTX $0.57
- Resistance Level
- ISDR $9.82
- BCTX $0.66
- Average True Range (ATR)
- ISDR 0.30
- BCTX 0.13
- MACD
- ISDR -0.05
- BCTX -0.05
- Stochastic Oscillator
- ISDR 52.14
- BCTX 0.00
About ISDR Issuer Direct Corporation
Issuer Direct Corp is a communications and compliance company. It focuses on the needs of corporate issuers. It provides disclosure management solutions, shareholder communications tools, and cloud-based compliance technologies. Its customers include public and private companies, mutual funds, law firms, brokerage firms, investment banks, individuals, and other institutions. Its products include PR solutions, IR solutions, Compliance, and Event management software.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.